Early detection of lung cancer can save smokers' lives

SEVEN NEWS. LUNG CANCER REMAINS THE LEADING CAUSE OF CANCER RELATED DEATH IN THE UNITED STATES. AS MEDICAL EXPERT DOCTOR RAMO EXPLAINS, RECENT GUIDELINE CHANGES COULD HELP SAVE THOUSANDS OF LIVES. LUNG CANCER IS A DEADLY DISEASE. THE EARLIEST SYMPTOMS ARE …

From CT scans to blood tests: The future of lung cancer screening with AI

Lung cancer is the deadliest of all other cancers. It is a leading cause of cancer death in the world, contributing to 18·7% of all cancer-related deaths. In 2020 alone, it caused 17 lakh deaths globally. Common in low- and middle-income countries like …

Lung Cancer Is Rising in Non-Smokers. Scientists Are Looking for Causes

Although a lot fewer people are smoking cigarettes, lung cancer is still the leading cause of cancer-related deaths in the United States. Recent research has found that lung cancer is rising among people who have never smoked, especially in women and Asian …

Why We Don’t Talk About Lung Cancer Early Enough

Unlike breast or cervical cancer, lung cancer isn’t widely discussed in families or the media until it becomes advanced. And unlike a breast lump or skin mole, early lung cancer doesn’t give you obvious signs. It creeps in silently — sometimes with a vague …

University of Kentucky HealthCare now offering same-day lung cancer diagnosis, treatment

FDA Grants Accelerated Approval to Boehringer’s HERNEXEOS for HER2-Mutant Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to HERNEXEOS (zongertinib tablets), Boehringer Ingelheim’s new oral targeted therapy for adults with previously treated, HER2-mutant advanced non-small cell lung cancer (NSCLC). …

UK HealthCare now offering same-day lung cancer diagnosis, treatment

LEXINGTON, Ky. (LEX 18) — The University of Kentucky Markey Cancer Center is showcasing same-day lung cancer diagnosis and treatment technology. It's in a demonstration in a state-of-the art mobile semi-truck. "We can tell them, 'Yes, it's …

New strategy to boost the effect of immunotherapy in the most aggressive form of lung cancer

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research Institute, in collaboration with researchers from the …

Novel Approach Enhances Immunotherapy Effectiveness Against the Most Aggressive Lung Cancer

In a groundbreaking development for the treatment of small cell lung cancer (SCLC), researchers have identified a novel therapeutic strategy that significantly boosts the efficacy of existing chemo-immunotherapy protocols. Spearheaded by the Hospital del …

Embracing uncertainty in precision medicine communications for lung cancer

An infusion in the morning versus the afternoon. That’s it. Yet this simple difference translated into a median progression-free survival (PFS) of 11.3 months versus 5.7 months for patients with non-small-cell lung cancer (NSCLC) receiving …